Table 1.
Patient Characteristics at Baseline
| Characteristic | N=15 | % |
|---|---|---|
| Median age (range) | 68 (52–78) | |
|
| ||
| Median PSA (range) | 261 (46–1705) | |
|
| ||
| Median Gleason Score (range) | 8 (5–10) | |
|
| ||
| Median Hemoglobin (range) | 11.6 (9.3–14.3) | |
|
| ||
| Median Alkaline Phosphate (range) | 154 (52–323) | |
|
| ||
| Median Days Since Last Chemotherapy (range) | 91 (28–925) | |
|
| ||
| Performance Status | ||
| 0 | 4 | 27 |
| 1 | 10 | 67 |
| 2 | 1 | 6 |
|
| ||
| Receiving concurrent zoledronic acid | ||
| yes | 9 | 60 |
| no | 6 | 40 |
|
| ||
| Race | ||
| white | 12 | 80 |
| black | 3 | 20 |
|
| ||
| Hypercalcemia | ||
| no | 15 | 100 |
|
| ||
| Prostatectomy | ||
| yes | 5 | 33 |
| no | 10 | 67 |
|
| ||
| Chemotherapy | ||
| Taxane based | 13 | 87 |
| Other | 2 | 13 |
|
| ||
| Radiation Therapy | ||
| yes | 12 | 80 |
| no | 3 | 20 |
|
| ||
| Androgen ablation | ||
| yes | 14 | 93 |
| no | 1 | 7 |
|
| ||
| Other Treatment | ||
| yes | 9 | 60 |
| no | 6 | 40 |
|
| ||
| Site of Disease - Visceral | ||
| yes | 6 | 40 |
| no | 9 | 60 |
|
| ||
| Site of Disease - Bone | ||
| yes | 11 | 73 |
| no | 4 | 27 |
|
| ||
| Site of Disease – Soft Tissue | ||
| yes | 4 | 27 |
| no | 11 | 73 |
|
| ||
| Other Site | ||
| yes | 9 | 60 |
| no | 6 | 40 |
|
| ||
| Disease Status | ||
| measurable | 2 | 13 |
| measurable & evaluable | 9 | 60 |
| evaluable, not measurable | 4 | 27 |